Soros Fund Management LLC Acquires Shares of 206,583 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Soros Fund Management LLC purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 206,583 shares of the biotechnology company's stock, valued at approximately $25,800,000. Soros Fund Management LLC owned 0.22% of Sarepta Therapeutics as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Innealta Capital LLC bought a new stake in Sarepta Therapeutics in the second quarter valued at about $31,000. Huntington National Bank raised its position in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 175 shares during the period. Nkcfo LLC bought a new position in Sarepta Therapeutics during the 2nd quarter worth approximately $43,000. Riggs Asset Managment Co. Inc. grew its holdings in Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 75 shares during the period. Finally, UMB Bank n.a. increased its stake in Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 197 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on SRPT shares. UBS Group raised their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a "buy" rating in a research note on Tuesday, September 17th. Robert W. Baird dropped their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. William Blair upgraded shares of Sarepta Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Needham & Company LLC dropped their price objective on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a "buy" rating on the stock in a report on Wednesday, November 27th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $175.55.

Sarepta Therapeutics Stock Performance

Shares of SRPT traded up $1.87 during trading hours on Friday, hitting $128.15. The company had a trading volume of 155,904 shares, compared to its average volume of 1,234,558. Sarepta Therapeutics, Inc. has a 12 month low of $85.61 and a 12 month high of $173.25. The firm has a market cap of $12.24 billion, a price-to-earnings ratio of 101.02 and a beta of 0.77. The business has a fifty day moving average of $122.64 and a 200-day moving average of $131.33. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.